|
RCUS | Arcus Biosciences, Inc. |
|
|
RCUS | Arcus Biosciences, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.23 |
| Leverage | 55.24% |
| Market Cap | $ 1.9B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -339.5m |
| Margin | -123.50% |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.